
The FDA has granted breakthrough therapy designation to ficerafusp alfa with Keytruda for some patients with head and neck squamous cell carcinoma.
A nationally-published, award-winning journalist, Alex Biese joined the CURE team as an assistant managing editor in April 2023. Prior to that, Alex's work was published in outlets including the Chicago Sun-Times, MTV.com, USA TODAY and the Press of Atlantic City. Alex is a member of NLGJA: The Association of LGBTQ+ Journalists, and also performs at the Jersey Shore with the acoustic jam band Somewhat Relative.
The FDA has granted breakthrough therapy designation to ficerafusp alfa with Keytruda for some patients with head and neck squamous cell carcinoma.
CURE spoke with Dr. Komal Jhaveri about the findings of the EMBER-3 clinical trial.
CURE spoke with melanoma survivor Betsy Hamlin about her experience with subcutaneous Keytruda in a clinical trial.
From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.
The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.
Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.
The FDA has approved Libtayo for the postsurgical treatment of adults with cutaneous squamous cell carcinoma.
In locally recurrent inoperable or metastatic TNBC, Datroway resulted in improvement in overall survival and progression-free survival.
The New Jersey retreat is free for women during and two years after cancer treatment.
The author and advocate, facing leukemia for the third time in 15 years, sat down for an interview with CURE.
Neuroblastoma is the most common cancer in infants and most commonly occurs in children younger than 5 years old.
The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.
A diagnosis of esophageal cancer can bring up many questions and concerns. Our goal is to provide you with clear, accurate and educational information.
For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.
Napo Pharmaceuticals applied for orphan drug designation for Mytesi to treat diarrhea in patients with breast cancer and brain metastases on targeted therapy.
Enhertu significantly improved invasive disease-free survival when compared with Kadcyla in high-risk HER2-positive early breast cancer.
Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.
Utidelone, previously received orphan drug designation from the FDA for the treatment of breast cancer brain metastases and gastric cancer.
Women with a history of cervical cancer are nearly twice as likely to develop anal cancer as members of the general population, according to researchers.
CURE spoke with Amanda Davis at the John Theurer Cancer Center in Hackensack, New Jersey.
CURE spoke with nurse and breast cancer survivor Amanda Davis at the John Theurer Cancer Center.
Non-melanoma skin cancer is a common and highly treatable type of cancer that originates in the top layer of the skin, like basal cell carcinoma.
Among patients with pancreatic cancer, the vaccine ELI-002 7P elicited strong mKRAS-specific T cell responses in approximately 99% of patients.
For patients with advanced GIST, complete surgical removal of metastases and full response to Gleevec are associated with roughly double the survival time.
For patients with myelofibrosis, there is a risk of non-melanoma skin cancer or shingles among patients who received long-term treatment with Jakafi.
For men with prostate cancer, radical prostatectomy, or surgical removal of the prostate, isn’t guaranteed to be curative, as one expert explained.
For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.
This guide is designed to help you understand liver cancer and equip you with the right questions to ask your medical team.
Perioperative immunotherapy for the treatment of non-small cell lung cancer is starting to exhibit survival benefits among patients, research has shown.
The FDA has accepted a new drug application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
Published: August 22nd 2025 | Updated: August 25th 2025
Published: April 12th 2025 | Updated: July 2nd 2025
Published: November 5th 2024 | Updated: May 19th 2025
Published: March 19th 2025 | Updated:
Published: January 29th 2024 | Updated:
Published: April 30th 2024 | Updated: